Abstract:Reprogramming fibroblasts into induced cardiomyocytes (iCMs) holds great potential for cardiac regeneration. However, low conversion rate both in vitro and in vivo remains a significant challenge. To address this challenge, we focused on potential epigenetic barriers and screened 33 small-molecule inhibitors/degraders targeting histone acetyl post-translational modifications and related epigenetic factors. BET degraders were found to enhance cardiac reprogramming efficiency by degrading BRD4 and repressing genes involved in immune response, particularly those in the JAK/STAT pathway. We further identified that macrophage/oncostatin M activated the JAK/STAT pathway to repress cardiac reprogramming. BRD4 degrader treatment improved iCMs formation by inhibiting macrophage/oncostatin M-induced activation of the JAK/STAT pathway. Moreover, BRD4 degrader treatment enhanced MGT-mediated cardiac regeneration in vivo and improved myocardial performance post-myocardial infarction. These findings provide new insights into BRD4, macrophage/oncostatin M and JAK/STAT pathway in fibroblast to cardiomyocyte-like cell conversion and offer promising targets and small molecules to improve iCM reprogramming for clinical applications.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the efficiency of cardiac reprogramming, especially to overcome the problem of low conversion rate by regulating histone acetylation. Specifically, the authors focus on how to inhibit the macrophage/oncostatin M (OSM) -induced JAK/STAT pathway by degrading BRD4 (a histone acetylation reader), thereby improving cardiac reprogramming. ### Detailed Interpretation: 1. **Research Background**: - Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and myocardial infarction (MI) is one of its major contributors. - Although current clinical treatments have improved the prognosis of patients, they have failed to address the fundamental problem of cardiomyocyte loss. - Direct reprogramming of fibroblasts into cardiomyocyte - like cells (iCMs) is a promising regenerative strategy, but it faces challenges such as low conversion rate and limited potential for in - vivo applications. 2. **Research Objectives**: - To improve the efficiency of cardiac reprogramming, especially under in - vivo conditions. - To explore the role of histone acetylation in cardiac reprogramming and find effective chemical compounds to regulate this process. 3. **Research Methods**: - Thirty - three chemical substances related to histone acetylation were screened to evaluate their impact on cardiac reprogramming. - It was found that BET degraders (such as BETd - 246) can significantly improve the efficiency of cardiac reprogramming by degrading BRD4 and inhibiting the expression of genes related to the immune response and the JAK/STAT pathway. 4. **Key Findings**: - Transient degradation of BRD4 can promote cardiac reprogramming by inhibiting the macrophage/OSM - activated JAK/STAT pathway. - BETd - 246 treatment significantly increased the formation of induced cardiomyocytes (iCMs) and improved calcium transients and spontaneous beating function. - In in - vivo experiments, BRD4 degraders enhanced MGT - mediated cardiac regeneration and improved cardiac function after myocardial infarction. 5. **Conclusion**: - Histone acetylation is a promising target for cardiac reprogramming. - BRD4, as a key regulator of the JAK/STAT pathway, plays an important role in cardiac reprogramming. - Transient degradation of BRD4 can effectively improve the efficiency of cardiac reprogramming and provides potential targets and small - molecule tools for future clinical applications. ### Formula Display: There are few formulas involved in this article, mainly descriptions in the fields of biology and medicine. If further display of specific mathematical or physical formulas is required, please provide more detailed requirements.

Transient BRD4 degradation improves cardiac reprogramming by inhibiting macrophage/Oncostatin M induced JAK/STAT pathway

Abstract P324: Brd4 Degradation Enhances Cardiac Reprogramming And Regeneration By Inhibiting JAK/STAT Pathway

Macrophages suppress cardiac reprogramming of fibroblasts in vivo via IFN-mediated intercellular self-stimulating circuit

Improving Cardiac Reprogramming for Heart Regeneration in Translational Medicine

Abstract 11415: Enhancing Direct Cardiac Reprogramming Efficiency Using Small Molecules

FGF4 and ascorbic acid enhance the maturation of induced cardiomyocytes by activating JAK2–STAT3 signaling

Inhibition of BRD4 Attenuates Transverse Aortic Constriction- and TGF-β-induced Endothelial-Mesenchymal Transition and Cardiac Fibrosis.

Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction

Direct Reprogramming of Fibroblasts into Cardiomyocytes

Down-regulation of Beclin1 promotes direct cardiac reprogramming

Down-regulation of Beclin 1 promotes direct cardiac reprogramming

Chemical Enhancement of in Vitro and in Vivo Direct Cardiac Reprogramming.

Bmi1 is a Key Epigenetic Barrier to Direct Cardiac Reprogramming

Direct Cardiac Reprogramming as a Novel Therapeutic Strategy for Treatment of Myocardial Infarction.

Cardiac regeneration by direct reprogramming in this decade and beyond

BET Bromodomain Protein 4 (BRD4) Governance of Cardiovascular Disease Stress-related Cardiomyocyte Remodeling

Targeting Mll1 H3K4 Methyltransferase Activity to Guide Cardiac Lineage Specific Reprogramming of Fibroblasts

Direct cardiac reprogramming: Toward the era of multi-omics analysis.

Abstract We033: Heart-Specific Histone Methyltransferase SMYD1 Promotes Cardiac Maturation in the Direct Conversion of Human Fibroblasts into Cardiomyocytes.

A Loss of Function Screen of Epigenetic Modifiers and Splicing Factors During Early Stage of Cardiac Reprogramming

Recent advances and future prospects in direct cardiac reprogramming